206 related articles for article (PubMed ID: 30877389)
1. Improving Stability and Dissolution of Amorphous Clofazimine by Polymer Nano-Coating.
Gui Y; Chen Y; Chen Z; Jones KJ; Yu L
Pharm Res; 2019 Mar; 36(5):67. PubMed ID: 30877389
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting Surface Crystallization and Improving Dissolution of Amorphous Loratadine by Dextran Sulfate Nanocoating.
Zeng A; Yao X; Gui Y; Li Y; Jones KJ; Yu L
J Pharm Sci; 2019 Jul; 108(7):2391-2396. PubMed ID: 30831122
[TBL] [Abstract][Full Text] [Related]
3. Polymer Nanocoating of Amorphous Drugs for Improving Stability, Dissolution, Powder Flow, and Tabletability: The Case of Chitosan-Coated Indomethacin.
Li Y; Yu J; Hu S; Chen Z; Sacchetti M; Sun CC; Yu L
Mol Pharm; 2019 Mar; 16(3):1305-1311. PubMed ID: 30668120
[TBL] [Abstract][Full Text] [Related]
4. Amorphous Drug-Polymer Salt with High Stability under Tropical Conditions and Fast Dissolution: The Case of Clofazimine and Poly(acrylic acid).
Gui Y; McCann EC; Yao X; Li Y; Jones KJ; Yu L
Mol Pharm; 2021 Mar; 18(3):1364-1372. PubMed ID: 33522821
[TBL] [Abstract][Full Text] [Related]
5. Gelatin Nano-coating for Inhibiting Surface Crystallization of Amorphous Drugs.
Teerakapibal R; Gui Y; Yu L
Pharm Res; 2018 Jan; 35(1):23. PubMed ID: 29305725
[TBL] [Abstract][Full Text] [Related]
6. Surface Stabilization and Dissolution Rate Improvement of Amorphous Compacts with Thin Polymer Coatings: Can We Have It All?
Novakovic D; Peltonen L; Isomäki A; Fraser-Miller SJ; Nielsen LH; Laaksonen T; Strachan CJ
Mol Pharm; 2020 Apr; 17(4):1248-1260. PubMed ID: 32027513
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Physical Stability of Amorphous Drug Formulations via Dry Polymer Coating.
Capece M; Davé R
J Pharm Sci; 2015 Jun; 104(6):2076-2084. PubMed ID: 25902736
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.
Parikh T; Sandhu HK; Talele TT; Serajuddin AT
Pharm Res; 2016 Jun; 33(6):1456-71. PubMed ID: 26951566
[TBL] [Abstract][Full Text] [Related]
9. Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions.
Sakai T; Hirai D; Kimura SI; Iwao Y; Itai S
Int J Pharm; 2018 Apr; 540(1-2):171-177. PubMed ID: 29447848
[TBL] [Abstract][Full Text] [Related]
10. Effect of Particle Size and Polymer Loading on Dissolution Behavior of Amorphous Griseofulvin Powder.
Zheng K; Lin Z; Capece M; Kunnath K; Chen L; Davé RN
J Pharm Sci; 2019 Jan; 108(1):234-242. PubMed ID: 30472263
[TBL] [Abstract][Full Text] [Related]
11. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
12. Amorphous Drug-Polymer Salt with High Stability under Tropical Conditions and Fast Dissolution: The Challenging Case of Lumefantrine-PAA.
Yao X; Kim S; Gui Y; Chen Z; Yu J; Jones KJ; Yu L
J Pharm Sci; 2021 Nov; 110(11):3670-3677. PubMed ID: 34371071
[TBL] [Abstract][Full Text] [Related]
13. Impact of Aluminum Oxide Nanocoating on Drug Release from Amorphous Solid Dispersion Particles.
Moseson DE; Benson EG; Cao Z; Bhalla S; Wang F; Wang M; Zheng K; Narwankar PK; Simpson GJ; Taylor LS
Mol Pharm; 2023 Jan; 20(1):593-605. PubMed ID: 36346665
[TBL] [Abstract][Full Text] [Related]
14. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.
Greco K; Bogner R
Mol Pharm; 2010 Oct; 7(5):1406-18. PubMed ID: 20459092
[TBL] [Abstract][Full Text] [Related]
15. [Microcosmic mechanisms of amorphous indomethacin crystallization and the influence of nano-coating on crystallization].
Hui OY; Yi T; Zheng Q; Liu F
Yao Xue Xue Bao; 2011 Jun; 46(6):707-12. PubMed ID: 21882533
[TBL] [Abstract][Full Text] [Related]
16. Probing the effects of interfacial chemistry on the kinetics of phase transitions in amorphous and tetragonal zirconia nanocrystals.
Kirsch BL; Riley AE; Gross AF; Tolbert SH
Langmuir; 2004 Dec; 20(25):11247-54. PubMed ID: 15568882
[TBL] [Abstract][Full Text] [Related]
17. Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations.
Xie T; Taylor LS
Pharm Res; 2016 Mar; 33(3):739-50. PubMed ID: 26563205
[TBL] [Abstract][Full Text] [Related]
18. Surface characteristics and dissolution behavior of plasma-sprayed hydroxyapatite coating.
Sun L; Berndt CC; Khor KA; Cheang HN; Gross KA
J Biomed Mater Res; 2002 Nov; 62(2):228-36. PubMed ID: 12209943
[TBL] [Abstract][Full Text] [Related]
19. Atomic Layer Coating to Inhibit Surface Crystallization of Amorphous Pharmaceutical Powders.
Moseson DE; Benson EG; Nguyen HT; Wang F; Wang M; Zheng K; Narwankar PK; Taylor LS
ACS Appl Mater Interfaces; 2022 Sep; 14(36):40698-40710. PubMed ID: 36054111
[TBL] [Abstract][Full Text] [Related]
20. The effect of processing on the surface physical stability of amorphous solid dispersions.
Yang Z; Nollenberger K; Albers J; Moffat J; Craig D; Qi S
Eur J Pharm Biopharm; 2014 Nov; 88(3):897-908. PubMed ID: 25111184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
